💙 Methylene blue in septic shock: miracle, myth… or misunderstood tool? We all know the scenario: 👉 Refractory vasoplegic shock 👉 Escalating norepinephrine 👉 Vasopressin, steroids… still hypotensive At some point, the question comes: Should we use methylene blue? ⚡ Mechanism Septic shock = NO-driven vasoplegia Methylene blue acts by: ❌ Inhibiting nitric oxide synthase (NOS) ❌ Blocking soluble guanylate cyclase ⬇️ Reducing cGMP ➡️ Restoring vascular tone 👉 A true catecholamine-sparing strategy 📊 What does the evidence say? Reality check: Use in practice is rare (~0.5% of septic shock patients) Often used as late salvage therapy Dosing strategies = highly variable But RCT signals are interesting: ↓ Vasopressor duration ↓ ICU / hospital length of stay Possible ↓ mortality (low certainty) 👉 Evidence is promising… but still weak 🚨 The clinical dilemma Timing is everything: Early use → potential physiologic benefit Late use → often too late to change trajectory 👉 Current practice is probably backwards ⚠️ What about safety? Potential concerns: Serotonin syndrome (with SSRIs) Pulmonary vasoconstriction G6PD-related hemolysis Interference with pulse oximetry 👉 Most serious effects seen with high doses 🧠 Take-home message > Methylene blue is not a “magic drug” but it may be a physiology-driven adjunct in vasoplegic shock ❓The real questions are: Who benefits? When to give it? At what dose? 🚀 Where we’re heading Ongoing trials (e.g., BLUSH trial) will clarify: ✔️ Early vs late use ✔️ Optimal dosing strategy ✔️ True impact on mortality 👉 This could redefine vasoplegic shock management 💡 Clinical reflection Next time you face refractory shock, ask: 👉 Is this still “fluid + catecholamine problem”… 👉 or already a NO-mediated vasoplegia problem? 📚 Reference Fernando, S. M.et al. Journal of Critical Care, 92, 155353. doi.org/10.1016/j.jcrc.2025.…